GGrantIndex
← Leaderboards

Julia H. Arnsten

Montefiore Medical Center (Bronx, Ny)

$18,953,214
Attributed
$29,858,803
Total exposure
9
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.9M · FY200525
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$29,858,803 · 9

By mechanism

RM1$13,727,424 · 1
R01$11,366,643 · 4
R25$4,049,137 · 2
P20$522,470 · 1
P30$193,129 · 1

Top collaborators

Most similar at Montefiore Medical Center (Bronx, Ny)

Same institution · by research overlap

Others in their field

Top investigators on “Persons

Research focus

PersonsEpidemiologyInnovationTrainingHiv InfectionsResearch PersonnelResourcesMentorsDrug UserDrug AddictionMethadoneResearch Project GrantsDiagnosisInstitutionPhysiciansFundingRecording Of Previous EventsProgramsDesignCaringBuprenorphineCommunitiesClinical ResearchDrug Abuse

Grant awards (43)

Integrated Care for Chronic Pain and Opioid Use Disorder: The IMPOWR Research Center at Montefiore/Einstein (IMPOWR-ME)$2,465,699
RM1 · FY2025 · DA
Integrated Care for Chronic Pain and Opioid Use Disorder: The IMPOWR Research Center at Montefiore/Einstein (IMPOWR-ME)$1,328,798
RM1 · FY2025 · DA
Integrated Care for Chronic Pain and Opioid Use Disorder: The IMPOWR Research Center at Montefiore/Einstein (IMPOWR-ME)$2,371,942
RM1 · FY2024 · DA
Integrated Care for Chronic Pain and Opioid Use Disorder: The IMPOWR Research Center at Montefiore/Einstein (IMPOWR-ME)$2,428,171
RM1 · FY2023 · DA
Integrated Care for Chronic Pain and Opioid Use Disorder: The IMPOWR Research Center at Montefiore/Einstein (IMPOWR-ME)$5,132,814
RM1 · FY2021 · DA
Does medical cannabis reduce opioid analgesics in HIV+ and HIV- adults with pain?$733,464
R01 · FY2021 · DA · contact PI
Patient and Population Health Outcomes Research SWG$40,677
P30 · FY2021 · AI · contact PI
Does medical cannabis reduce opioid analgesics in HIV+ and HIV- adults with pain?$751,280
R01 · FY2020 · DA · contact PI
Patient and Population Health Outcomes Research SWG$40,060
P30 · FY2020 · AI · contact PI
Patient and Population Health Outcomes Research SWG$38,867
P30 · FY2019 · AI · contact PI
Patient and Population Health Outcomes Research SWG$14,579
P30 · FY2018 · AI · contact PI
Patient and Population Health Outcomes Research SWG$6,946
P30 · FY2018 · AI · contact PI
Patient and Population Health Outcomes Research SWG$52,000
P30 · FY2017 · AI · contact PI
Neurocognitive Effects of Opiate Agonist Treatment in HIV Infected Drug Users$614,813
R01 · FY2016 · DA · contact PI
Neurocognitive Effects of Opiate Agonist Treatment in HIV Infected Drug Users$520,108
R01 · FY2015 · DA · contact PI
Neurocognitive Effects of Opiate Agonist Treatment in HIV Infected Drug Users$109,119
R01 · FY2015 · DA · contact PI
Neurocognitive Effects of Opiate Agonist Treatment in HIV Infected Drug Users$675,282
R01 · FY2014 · DA · contact PI
HIV and Substance Abuse Clinical Addiction Research and Education (CARE) Program$235,949
R25 · FY2014 · DA · contact PI
HIV and Substance Abuse Clinical Addiction Research and Education (CARE) Program$117,975
R25 · FY2014 · DA · contact PI
Neurocognitive Effects of Opiate Agonist Treatment in HIV Infected Drug Users$658,835
R01 · FY2013 · DA · contact PI
HIV and Substance Abuse Clinical Addiction Research and Education (CARE) Program$344,842
R25 · FY2013 · DA · contact PI
Neurocognitive Effects of Opiate Agonist Treatment in HIV Infected Drug Users$708,322
R01 · FY2012 · DA · contact PI
HIV and Substance Abuse Clinical Addiction Research and Education (CARE) Program$367,343
R25 · FY2012 · DA · contact PI
HIV and Substance Abuse Clinical Addiction Research and Education (CARE) Program$375,598
R25 · FY2011 · DA · contact PI
Neurocognitive Effects of Buprenorphine Among HIV+ Opioid Users$165,637
P20 · FY2011 · DA · contact PI
Clinical Addiction Research and Education Program$322,728
R25 · FY2010 · DA · contact PI
Neurocognitive Effects of Buprenorphine Among HIV+ Opioid Users$171,279
P20 · FY2010 · DA · contact PI
Clinical Addiction Research and Education Program$325,987
R25 · FY2009 · DA · contact PI
Neurocognitive Effects of Buprenorphine Among HIV+ Opioid Users$185,554
P20 · FY2009 · DA · contact PI
Clinical Addiction Research and Education Program$325,987
R25 · FY2008 · DA · contact PI
Efficacy and cost of HAART DOT in methadone clinics$584,081
R01 · FY2007 · DA · contact PI
Clinical Addiction Research and Education Program$332,640
R25 · FY2007 · DA · contact PI
Efficacy and cost of HAART DOT in methadone clinics$1,070,849
R01 · FY2006 · DA · contact PI
Efficacy and cost of HAART DOT in methadone clinics$1,067,167
R01 · FY2005 · DA
CLINICAL ADDICTION RESEARCH AND EDUCATION (CARE) PROGRAM$337,133
R25 · FY2005 · DA
Efficacy and cost of HAART DOT in methadone clinics$1,038,565
R01 · FY2004 · DA
CLINICAL ADDICTION RESEARCH AND EDUCATION (CARE) PROGRAM$328,120
R25 · FY2004 · DA
Efficacy and cost of HAART DOT in methadone clinics$1,017,554
R01 · FY2003 · DA
CLINICAL ADDICTION RESEARCH AND EDUCATION (CARE) PROGRAM$319,366
R25 · FY2003 · DA
CLINICAL ADDICTION RESEARCH AND EDUCATION (CARE) PROGRAM$315,469
R25 · FY2002 · DA
HIV THERAPY ADHERENCE AND VIRAL RESISTANCE IN DRUG USERS$202,085
R01 · FY2002 · DA
HIV THERAPY ADHERENCE AND VIRAL RESISTANCE IN DRUG USERS$768,624
R01 · FY2001 · DA
HIV THERAPY ADHERENCE AND VIRAL RESISTANCE IN DRUG USERS$846,495
R01 · FY2000 · DA